Journal of Gastroenterology

, Volume 46, Issue 4, pp 501–509

High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b

  • Hidenori Toyoda
  • Takashi Kumada
  • Seiki Kiriyama
  • Makoto Tanikawa
  • Yasuhiro Hisanaga
  • Akira Kanamori
  • Toshifumi Tada
  • Takahiro Arakawa
  • Masashi Fujimori
  • Takuro Niinomi
  • Naoto Ando
  • Satoshi Yasuda
  • Keisuke Sakai
  • Jun Kimura
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

The ability to predict the outcome of peginterferon (PEG-IFN) and ribavirin combination therapy based on the reduction in hepatitis C virus (HCV) RNA levels at 4 weeks after starting the therapy and amino acid substitutions in HCV was to be confirmed.

Methods

We measured the reduction in HCV RNA levels at 4 weeks after starting the combination therapy, as well as examining amino acid substitutions at residue 70 in the HCV core and within the interferon sensitivity-determining region (ISDR) of HCV non-structural protein 5A (NS5A), for 101 patients infected with HCV genotype 1b. The ability of these factors to predict a sustained virologic response (SVR) was analyzed.

Results

When a 3 log10 reduction in HCV RNA levels at 4 weeks after starting therapy was set as the cut-off value, an SVR was achieved in 37 of the 46 patients (80.4%) with a ≥3 log10 decrease and in 4 of the 55 patients (7.3%) with a <3 log10 decrease. All 4 patients who achieved an SVR despite a <3 log10 reduction in HCV RNA levels at 4 weeks had an arginine at residue 70 in the HCV core and a non-wild-type sequence for the ISDR of HCV NS5A.

Conclusion

A ≥3 log10 reduction in HCV RNA levels at 4 weeks after starting therapy indicates that a patient has a high likelihood of achieving an SVR as a final outcome. Additional information on the amino acid substitutions at residue 70 in the HCV core and within NS5A-ISDR will further increase the ability to predict a clinical response.

Keywords

Chronic hepatitis C Four weeks Peginterferon Reduction in HCV RNA Response-guided therapy Ribavirin 

References

  1. 1.
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.PubMedCrossRefGoogle Scholar
  2. 2.
    Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol. 2009;44:1009–15.PubMedCrossRefGoogle Scholar
  3. 3.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology. 2007;50:361–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007;81:8211–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Watanabe H, Nagayama K, Enomoto N, Itakura J, Tanabe Y, Sato C, et al. Amino acid substitutions in PKR-eIF2 phosphorylation homology domain (PePHD) of hepatitis C virus E2 protein in genotype 2a/2b and 1b in Japan and interferon efficacy. Hepatol Res. 2003;26:268–74.Google Scholar
  6. 6.
    Yang SS, Lai MY, Chen DS, Chen GH, Kao JH. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver Int. 2003;23:426–33.PubMedCrossRefGoogle Scholar
  7. 7.
    de Rueda PM, Casado J, Paton R, Quintero D, Palacios A, Gila A, et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A–V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J Virol. 2008;82:6644–53.CrossRefGoogle Scholar
  8. 8.
    Welker MW, Hofmann WP, Welsch C, von Wagner M, Herrmann E, Lengauer T, et al. Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon-alpha-based therapy in HCV-1b-infected patients. J Viral Hepat. 2007;14:338–49.Google Scholar
  9. 9.
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77–81.PubMedCrossRefGoogle Scholar
  10. 10.
    El-Shamy A, Nagano-Fujii M, Sasae N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. Hepatology. 2008;48:38–47.PubMedCrossRefGoogle Scholar
  11. 11.
    Bouzgarrou N, Hassen E, Mahfoudh W, Gabbouj S, Schvoerer E, Ben Yahia A, et al. NS5AISDR-V3 region genetic variability of Tunisian HCV-1b strains: correlation with the response to the combined interferon/ribavirin therapy. J Med Virol. 2009;81:2021–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Okanoue T, Itoh Y, Hashimoto H, Yasui K, Minami M, Takehara T, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol. 2009;44:952–63.PubMedCrossRefGoogle Scholar
  13. 13.
    Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology. 2001;120:1438–47.PubMedCrossRefGoogle Scholar
  14. 14.
    Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, et al. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology. 2002;35:930–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology. 2003;37:600–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. Antiviral Ther. 2008;13:S9–16.Google Scholar
  17. 17.
    Marcellin P, Rizzetto M. Response-guided therapy: optimizing treatment now and in the future. Antiviral Ther. 2008;13:S1–2.Google Scholar
  18. 18.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;345:975–82.CrossRefGoogle Scholar
  19. 19.
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38:645–52.PubMedCrossRefGoogle Scholar
  20. 20.
    Martinez-Bauer E, Crespo J, Romero-Gomez M, Moreno-Otero R, Sola R, Tesei N, et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology. 2006;43:72–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis. 2008;46:78–84.PubMedCrossRefGoogle Scholar
  22. 22.
    Martinot-Peignoux M, Maylin S, Moucari R, Ripault M-P, Boyer N, Cardoso A-C, et al. Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Antivir Ther. 2009;14:501–11.PubMedGoogle Scholar
  23. 23.
    de Segadas-Soares JA, Villela-Nogueira CA, Perez RM, Nabuco LC, Brandao-Mello CE, Coelho HSM. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis C patients treated with peginterferon-α2b and ribavirin? J Clin Gastroenterol. 2009;43:362–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Colucci G, Ferguson J, Harkleroad C, Lee S, Romo D, Soviero S, et al. Improved COBAS TaqMan hepatitis C virus test (version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol. 2007;45:3595–600.PubMedCrossRefGoogle Scholar
  25. 25.
    Pittaluga F, Allice T, Abate ML, Ciancio A, Cerutti F, Varetto S, et al. Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay. J Med Virol. 2008;80:254–60.PubMedCrossRefGoogle Scholar
  26. 26.
    Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA. 1990;87:9524–8.PubMedCrossRefGoogle Scholar
  27. 27.
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15–20.CrossRefGoogle Scholar
  28. 28.
    Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Ferenci P, Laferl H, Scherzer TM, Gschwantker M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451–8.Google Scholar
  30. 30.
    Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology. 2008;47:43–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008;47:1884–93.PubMedCrossRefGoogle Scholar
  32. 32.
    Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-α-2a plus ribavirin for treatment-naïve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatment-naïve genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol. 2010;52:25–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon α-2a and ribavirin. J Gastroenterol Hepatol. 2007;22:832–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, Hou NJ, et al. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol. 2010;25:758–65.PubMedCrossRefGoogle Scholar
  36. 36.
    Deltenre P, Canva V, El Nady M, Francois C, Castelain S, Dharancy S, et al. A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study. J Viral Hepat. 2009;16:500–5.PubMedCrossRefGoogle Scholar
  37. 37.
    Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086–97.PubMedCrossRefGoogle Scholar
  38. 38.
    Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology. 2007;46:1688–94.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Hidenori Toyoda
    • 1
  • Takashi Kumada
    • 1
  • Seiki Kiriyama
    • 1
  • Makoto Tanikawa
    • 1
  • Yasuhiro Hisanaga
    • 1
  • Akira Kanamori
    • 1
  • Toshifumi Tada
    • 1
  • Takahiro Arakawa
    • 1
  • Masashi Fujimori
    • 1
  • Takuro Niinomi
    • 1
  • Naoto Ando
    • 1
  • Satoshi Yasuda
    • 1
  • Keisuke Sakai
    • 1
  • Jun Kimura
    • 1
  1. 1.Department of GastroenterologyOgaki Municipal HospitalOgakiJapan

Personalised recommendations